Skip to main content
Log in

Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn—a prospective randomized controlled trial

  • Original Paper
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Phototherapy is the standard treatment in moderately severe hemolytic disease of newborn (HDN), whereas exchange transfusion (ET) is the second line in progressive cases. Intravenous immunoglobin (IVIG) has been suggested to decrease the need for ET. We aimed at assessing the efficacy of early two-dose regimens of IVIG to avoid unnecessary ET in severe Rh HDN. The study included 90 full-term neonates with Rh incompatibility unmodified by antenatal treatment and not eligible for early ET and which were randomly assigned into one of three groups: group (I), treated by conventional method; groups IIa and IIb received IVIG once at 12 h postnatal age if PT was indicated, in a dose of 0.5 and 1 g/kg, respectively. Analysis revealed 11 neonates (22%) in the conventional group and 2 (5%) in the intervention group who administered low-dose IVIG at 12 h, while none in group IIb required exchange transfusion (p = 0.03). Mean bilirubin levels were significantly lower during the first 96 h in the intervention group compared to the conventional group (p < 0.0001). Shorter duration of phototherapy (52.8 ± 12.39 h) and hospital stay (3.25 ± 0.71 days) in the IVIG group compared to conventional group (84 ± 12.12 h and 4.72 ±0.78 days, p < 0.0001, respectively) were observed. We conclude that IVIG administration at 12 h was effective in the treatment of severe Rh HDN; the low-dose IVIG (0.5 g/kg) was as effective as high dose (1 g/kg) in reducing the duration of phototherapy and hospital stay, but less effective in avoiding exchange transfusion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Alpay F, Sarici SU, Okutan V, Erdem G, Ozcan O, Gokcay E (1999) High dose intravenous immunoglobulin therapy in neonatal immune hemolytic jaundice. Acta Paediatr 88(2):216–219

    Article  PubMed  CAS  Google Scholar 

  2. American Academy of Pediatrics (2004) Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation (Subcommittee on Hyper-bilirubinemia). Pediatrics 114(1):297–316

    Article  Google Scholar 

  3. Behjati Sh, Sagheb S, Aryasepehr S, Yaghmai B (2009) Adverse events associated with neonatal exchange transfusion for hyperbilirubinemia. Indian J Pediatr 76(1):83–85

    Article  PubMed  Google Scholar 

  4. Colletti JE, Kothari S, Jackson DM, Kilgore KP, Barringer K (2007) An emergency medicine approach to neonatal hyperbilirubinemia. Emerg Med Clin North Am 25(4):1117–1135, vii

    Article  PubMed  Google Scholar 

  5. Cooper N (2009) Intravenous immunoglobulin and anti-Rh D therapy in the management of immune thrombocytopenia. Hematol Oncol Clin North Am 23(6):1317–1327

    Article  PubMed  Google Scholar 

  6. Cortey A, Brossard Y (2006) Prevention of fetomaternal rhesus-D allo-immunization. Practical aspects. J Gynecol Obstet Biol Repord (Paris) 35(1 suppl):1S123–1S130

    CAS  Google Scholar 

  7. Demirel N, Aydin M, Zenciroglu A, Bas AY, Yarali N, Okumus N, Cinar G, Ipek MS (2009) Neonatal thrombo-embolism: risk factors, clinical features and outcome. Ann Trop Paediatr Dec 29(4):271–279

    Article  CAS  Google Scholar 

  8. Figueras-Aloy J, Rodriguez-Miguelez JM, Iriondo-Sanz M et al (2010) Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease. Pediatrics 125(1):139–144

    Article  PubMed  Google Scholar 

  9. Girish G, Chawla D, Agarwal R, Paul VK, Deorari Ak (2008) Efficacy of two dose regimes of intravenous immunoglobulin in Rh hemolytic disease of newborn—a randomized controlled trial. Indian Pediatr 45(8):653–659

    PubMed  CAS  Google Scholar 

  10. Gobalakichenane P, Lardennois C, Galène-Gromez S et al (2008) Perinatal management and neurological outcome of newborns hospitalized with rhesus hemolytic disease. Gynécol Obstét Fertil 36(10):984–990

    Article  PubMed  CAS  Google Scholar 

  11. Gordon S (2001) Mononuclear phagocytes in immune defense. In: Roitt I, Brostoff J, Male D (eds) Immunology, 6th edn. Mosby, St. Louis, pp 155–156

    Google Scholar 

  12. Gottstein R, Cooke RW (2003) Systemic review of intravenous immunoglobulin in hemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 88(1):F6–F10

    Article  PubMed  CAS  Google Scholar 

  13. Greenough A (1999) Rhesus disease: postnatal management and outcome. Eur J Pediatr 158(9):689–693

    Article  PubMed  CAS  Google Scholar 

  14. Hammerman C, Kaplan M (2000) Recent developments in the management of neonatal hyperbilirubinemia. NeoReviews 1:19–24

    Article  Google Scholar 

  15. Huizing K, Røislien J, Hansen T (2008) Intravenous immune globulin reduces the need for exchange transfusions in rhesus and AB0 incompatibility. Acta Paediatr 97(10):1362–1365

    Article  PubMed  CAS  Google Scholar 

  16. Kirk JM (2008) Neonatal jaundice: a critical review of the role and practice of bilirubin analysis. Ann Clin Biochem 45(pt5):452–462

    Article  PubMed  CAS  Google Scholar 

  17. Kriplani A, Malhotra Singh B, Mandal K (2007) Fetal intravenous immunoglobulin therapy in rhesus hemolytic disease. Gynecol Obstet Invest 63(3):176–180

    Article  PubMed  Google Scholar 

  18. Maisels MJ, McDonagh Ak (2008) Phototherapy for neonatal jaundice. N Engl J Med 358(9):920–928

    Article  PubMed  CAS  Google Scholar 

  19. Malhotra A, Carse E (2009) Survey of management of neonatal haemolytic jaundice in Australasia. J Paediatr Child Health 46(5):222–225

    Article  Google Scholar 

  20. Miqdad AM, Abdelbasit OB, Shaheed MM, Seidahmed Mz, Abomella AM, Arcala OP (2004) Intravenous immunoglobulin therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. J Matern Fetal Neonatal Med 6(3):163–166

    Article  Google Scholar 

  21. Moise KJ (2008) Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 112(1):164–176

    Article  PubMed  Google Scholar 

  22. Monpoux F, Dageville C, Maillotte AM, De Smet S, Casagrande F, Boutté P (2009) High-dose intravenous immunoglobulin therapy and neonatal jaundice due to red blood cell alloimmunization. Arch Pediatr 16(9):1289–1294

    Article  PubMed  CAS  Google Scholar 

  23. Mukhopadhyay K, Murki S, Narang A, Dutta S (2003) Intravenous immunoglobulin in rhesus hemolytic disease. Indian J Pediatr 70(9):697–699

    Article  PubMed  Google Scholar 

  24. Mundy CA (2005) Intravenous immunoglobulin in the management of hemolytic disease of the newborn. Neonatal Netw 24(6):17–24

    PubMed  Google Scholar 

  25. Murray NA, Roberts IA (2007) Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 92(2):F83–F88

    Article  PubMed  Google Scholar 

  26. Navarro M, Negre S, Golombek S, Matoses ML, Vento M (2010) Intravenous immune globulin: clinical applications in the newborn. NeoReviews 11(7):e370–e378

    Article  Google Scholar 

  27. Oepkes D, Adama van Scheltema P (2007) Intrauterine fetal transfusions in the management of fetal anemia and fetal thrombocytopenia. Semin Fetal Neonatal Med 12(6):432–438

    Article  PubMed  Google Scholar 

  28. Roberts IA (2008) The changing face of haemolytic disease of the newborn. Early Hum Dev 84(8):515–523

    Article  PubMed  Google Scholar 

  29. Smits S, Wintjens VE, Walther FJ, Lopriore E (2008) Rhesus hemolytic disease of the newborn: postnatal management, associated morbidity and long term outcome. Semin Fetal Neonatal Med 13(4):265–271

    Article  Google Scholar 

  30. Steiner LA, Bizzarro MJ, Ehrenkranz RA, Gallagher PG (2007) A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics 120(1):27–32

    Article  PubMed  Google Scholar 

  31. Tanyer G, Siklar Z, Dallar Y, Yildirmak Y, Tiras V (2001) Multiple dose intravenous immunoglobulin treatment in neonatal immune hemolytic jaundice. J Trop Pediatr 47(1):50–53

    Article  PubMed  CAS  Google Scholar 

  32. Voto L, Sexer H, Ferreiro G, Tavosnanska J, Orti J, Mathet ER, Margulies M (1995) Neonatal administration of high dose intravenous immunoglobulin in rhesus hemolytic disease. J Perinat Med 23(6):443–451

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interests

The authors declare that they have no conflict of interests.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mohsen Saleh Elalfy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elalfy, M.S., Elbarbary, N.S. & Abaza, H.W. Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn—a prospective randomized controlled trial. Eur J Pediatr 170, 461–467 (2011). https://doi.org/10.1007/s00431-010-1310-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-010-1310-8

Keywords

Navigation